Wire · opportunities
Caliway's CBL-514 Phase 2 Combination Trial Cleared; Phase 3 SUPREME-01 Enrolling
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 27 August 2026 · Fusion42 review
Caliway Biopharmaceuticals' FDA clearance for a Phase 2 trial combining CBL-514 with tirzepatide and the start of a pivotal Phase 3 trial SUPREME-01 signal significant clinical progress toward regulatory approval for a novel fat-reduction injectable targeting abdominal fat.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 26 Aug 2026 and 27 Aug 2026.
◆ ◆ The Wire takeaway
You can now position your metabolic or aesthetic biotech startup to leverage regulatory movement toward novel fat-reduction therapies combining pharma and biologics. This opens an early window to develop complementary mechanisms targeting weight regain beyond existing GLP-1 options.
◆ Coverage
2 sources · first reported 26 Aug 2026 · latest 27 Aug 2026
◆ Related on Wire
◆ Topics